Statera Biopharma Pink Sheet Forecast - Simple Regression
| STAB Stock | USD 0.0001 0.0003 75.00% |
The Simple Regression forecasted value of Statera Biopharma on the next trading day is expected to be 0.0002 with a mean absolute deviation of 0.000053 and the sum of the absolute errors of 0. Statera Pink Sheet Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Statera Biopharma stock prices and determine the direction of Statera Biopharma's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Statera Biopharma's historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time the relative strength index (rsi) of Statera Biopharma's share price is below 20 . This usually implies that the pink sheet is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using Statera Biopharma hype-based prediction, you can estimate the value of Statera Biopharma from the perspective of Statera Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Regression forecasted value of Statera Biopharma on the next trading day is expected to be 0.0002 with a mean absolute deviation of 0.000053 and the sum of the absolute errors of 0. Statera Biopharma after-hype prediction price | USD 8.9E-5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Statera |
Statera Biopharma Additional Predictive Modules
Most predictive techniques to examine Statera price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Statera using various technical indicators. When you analyze Statera charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Statera Biopharma Simple Regression Price Forecast For the 25th of January
Given 90 days horizon, the Simple Regression forecasted value of Statera Biopharma on the next trading day is expected to be 0.0002 with a mean absolute deviation of 0.000053, mean absolute percentage error of 0, and the sum of the absolute errors of 0.Please note that although there have been many attempts to predict Statera Pink Sheet prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Statera Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Statera Biopharma Pink Sheet Forecast Pattern
| Backtest Statera Biopharma | Statera Biopharma Price Prediction | Buy or Sell Advice |
Statera Biopharma Forecasted Value
In the context of forecasting Statera Biopharma's Pink Sheet value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Statera Biopharma's downside and upside margins for the forecasting period are 0.000001 and 50.33, respectively. We have considered Statera Biopharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Statera Biopharma pink sheet data series using in forecasting. Note that when a statistical model is used to represent Statera Biopharma pink sheet, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 98.9756 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 1.0E-4 |
| MAPE | Mean absolute percentage error | 0.3601 |
| SAE | Sum of the absolute errors | 0.0032 |
Predictive Modules for Statera Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Statera Biopharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Statera Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Statera Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Statera Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Statera Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Statera Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Statera Biopharma's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Statera Biopharma's historical news coverage. Statera Biopharma's after-hype downside and upside margins for the prediction period are 0.00 and 50.01, respectively. We have considered Statera Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Statera Biopharma is out of control at this time. Analysis and calculation of next after-hype price of Statera Biopharma is based on 3 months time horizon.
Statera Biopharma Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Statera Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Statera Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Statera Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
8.47 | 50.33 | 0.00 | 0.00 | 0 Events / Month | 2 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.0001 | 0.000089 | 10.56 |
|
Statera Biopharma Hype Timeline
Statera Biopharma is at this time traded for 0.0001. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Statera is forecasted to decline in value after the next headline, with the price expected to drop to 8.9E-5. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -10.56%, whereas the daily expected return is at this time at 8.47%. The volatility of related hype on Statera Biopharma is about 0.0%, with the expected price after the next announcement by competition of 0.00. About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.16. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Statera Biopharma recorded a loss per share of 0.76. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 28th of January 2015. Given the investment horizon of 90 days the next forecasted press release will be within a week. Check out Historical Fundamental Analysis of Statera Biopharma to cross-verify your projections.Statera Biopharma Related Hype Analysis
Having access to credible news sources related to Statera Biopharma's direct competition is more important than ever and may enhance your ability to predict Statera Biopharma's future price movements. Getting to know how Statera Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Statera Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ERGO | Entia Biosciences | 0.00 | 0 per month | 0.00 | 0.1 | 0.00 | 0.00 | 550.00 | |
| BTAX | Biostax Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| INFIQ | Infinity Pharmaceuticals | 0.00 | 8 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EVLO | Evelo Biosciences | 0.00 | 0 per month | 0.00 | 0.07 | 0.00 | (20.00) | 460.00 | |
| BTTX | Better Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BLMS | Bloomios | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| KLDO | Kaleido Biosciences | 0.00 | 0 per month | 0.00 | 0.16 | 0.00 | 0.00 | 4,998 | |
| HSTC | HST Global | 0.00 | 9 per month | 0.00 | 0.18 | 0.00 | 0.00 | 4,954 | |
| ONPH | Oncology Pharma | 0.00 | 0 per month | 25.86 | 0.20 | 200.00 | (66.67) | 1,995 | |
| SESI | SES Solar | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Forecasting Options for Statera Biopharma
For every potential investor in Statera, whether a beginner or expert, Statera Biopharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Statera Pink Sheet price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Statera. Basic forecasting techniques help filter out the noise by identifying Statera Biopharma's price trends.Statera Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Statera Biopharma pink sheet to make a market-neutral strategy. Peer analysis of Statera Biopharma could also be used in its relative valuation, which is a method of valuing Statera Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Statera Biopharma Market Strength Events
Market strength indicators help investors to evaluate how Statera Biopharma pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Statera Biopharma shares will generate the highest return on investment. By undertsting and applying Statera Biopharma pink sheet market strength indicators, traders can identify Statera Biopharma entry and exit signals to maximize returns.
| Rate Of Daily Change | 0.25 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 | |||
| Price Action Indicator | (0.0001) | |||
| Period Momentum Indicator | (0.0003) |
Statera Biopharma Risk Indicators
The analysis of Statera Biopharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Statera Biopharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting statera pink sheet prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 26.86 | |||
| Semi Deviation | 21.36 | |||
| Standard Deviation | 48.8 | |||
| Variance | 2381.26 | |||
| Downside Variance | 4409.72 | |||
| Semi Variance | 456.09 | |||
| Expected Short fall | (118.75) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Statera Biopharma
The number of cover stories for Statera Biopharma depends on current market conditions and Statera Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Statera Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Statera Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Statera Biopharma Short Properties
Statera Biopharma's future price predictability will typically decrease when Statera Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Statera Biopharma often depends not only on the future outlook of the potential Statera Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Statera Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.1 M | |
| Cash And Short Term Investments | 2 M |
Other Information on Investing in Statera Pink Sheet
Statera Biopharma financial ratios help investors to determine whether Statera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Statera with respect to the benefits of owning Statera Biopharma security.